Development of gene therapy for the muscular dystrophies represents a daunting challenge requiring significant advances in our knowledge of the defective genes, muscle promoters, viral vectors, immune system surveillance and methods for systemic delivery of vectors. However, tremendous progress has been made in developing improved viral vectors and avoiding immune reactions against gene transfe...

Chapter 1 presents a review of the current literature on non-viral gene delivery with special emphasis on peptide gene delivery carriers and the use of acridine. Barriers to systemically-administered non-viral gene delivery and remedies to overcome them individually will be discussed, and two physical methods of particular importance in examining circulating polyplexes (DNA and peptide carrier)...

Acyclovir (ACV) is a promising candidate for drug repurposing because of its potential to provide an effective treatment viral infections and non-viral diseases, such as cancer, which limited options exist. However, poor physicochemical properties limit application. This study aimed formulate evaluate ACV-loaded red clay nanodrug delivery system exhibiting cytotoxicity. The focused on the prepa...